Specific Inhibition of Influenza Virus RNA Polymerase and Nucleoprotein Gene Expression by Liposomally Encapsulated Antisense Phosphorothioate Oligonucleotides in MDCK Cells
Open Access
- 1 June 1998
- journal article
- research article
- Published by SAGE Publications in Antiviral Chemistry and Chemotherapy
- Vol. 9 (3) , 253-262
- https://doi.org/10.1177/095632029800900306
Abstract
We have demonstrated that antisense phosphorothioate oligonucleotides (S-ODNs) inhibit influenza A virus replication in MDCK cells. Liposomally encapsulated and free antisense S-ODNs with four target sites (PB1, PB2, PA and NP genes) were tested for their abilities to inhibit virus-induced cytopathogenic effects in a MTT assay using MDCK cells. The liposomally encapsulated S-ODN complementary to the site around the PB2 AUG initiation codon showed highly inhibitory effects. In contrast, the inhibitory effect of the liposomally encapsulated S-ODN targeted to PB1 was considerably decreased in comparison with that directed to the PB2 target site. The liposomally encapsulated antisense S-ODNs exhibited higher inhibitory activities than the free oligonucleotides, and showed sequence-specific inhibition, whereas free antisense S-ODNs were observed to inhibit viral adsorption to MDCK cells. Liposomal preparations of oligonucleotides facilitated their release from endocytic vesicles, and thus cytoplasmic and nuclear localization was observed. The activities of the antisense S-ODNs were effectively enhanced by using the liposomal carrier. Interestingly, the liposomally encapsulated FITC-S-ODN-PB2–as accumulated in the nuclear region of MDCK cells. However, weak fluorescence was observed within the endosomes and the cytoplasm of MDCK cells treated with the free antisense S-ODNs. The cationic lipid particles may thus be a potentially useful delivery vehicle for oligonucleotide-based therapeutics and transgenes, appropriate for use in vitro or in vivo.Keywords
This publication has 51 references indexed in Scilit:
- Specific Inhibition of Influenza Virus RNA Polymerase and Nucleoprotein Genes Expression by Liposomally Endocapsulated Antisense Phosphorothioate Oligonucleotides: Penetration and Localization of Oligonucleotides in Clone 76 CellsBiochemical and Biophysical Research Communications, 1997
- Mechanisms of the inhibition of reverse transcription by unmodified and modified antisense oligonucleotidesFEBS Letters, 1993
- Anti-HIV activities and physicochemical properties of phosphorothioate analogues complementary to HIV sequencesBioorganic & Medicinal Chemistry Letters, 1993
- Liposome delivery of antisense oligonucleotides: adsorption and efflux characteristics of phosphorothioate oligodeoxynucleotidesJournal of Controlled Release, 1992
- Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivoNature, 1992
- Template. Phosphorothioate oligonucleotides duplexes as inhibitors of HIV-1 reverse transcriptaseBiochemical and Biophysical Research Communications, 1992
- Free and Liposome-Encapsulated Double-Stranded RNAs as Inducers of Interferon, Interleukin-6, and Cellular ToxicityJournal of Interferon Research, 1991
- A new class of antivirals: antisense oligonucleotides combined with a hydrophobic substituent effectively inhibit influenza virus reproduction and synthesis of virus‐specific proteins in MDCK cellsFEBS Letters, 1990
- Oligodeoxynucleotides as Anti-Sense Inhibitors of Gene Expression: Therapeutic ImplicationsJNCI Journal of the National Cancer Institute, 1989
- Automated solid-phase synthesis, separation, and stereochemistry of phosphorothioate analogs of oligodeoxyribonucleotidesJournal of the American Chemical Society, 1984